

## **Living with HIV: Understanding the Patient Experience and Appreciating the Science**

### **#HIVchat - Twitter Chat #2**

#### **References**

Back D, Marzolini C. The challenge of HIV treatment in an era of polypharmacy. *J Int AIDS Soc.* 2020;23(2):e25449. doi:10.1002/jia2.25449

Edelman EJ, Rentsch CT, Justice AC. Polypharmacy in HIV: recent insights and future directions. *Curr Opin HIV AIDS.* 2020;15(2):126-133. doi:10.1097/COH.0000000000000608

Gupta S, Sims J, Brinson C, et al. Lenacapavir as part of a combination regimen in treatment naïve PWH: week 54 results. Abstract 138. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/lenacapavir-as-part-of-a-combination-regimen-in-treatment-naive-pwh-week-54-results/>

Knechten H, Stephan C, Waizmann M, et al. Patient-reported outcomes (PROs) after 1 year of routine clinical practice with bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF): The BICSTaR cohort. Abstract P053. Presented at: HIV Glasgow; October 23-26 2020; Virtual. <https://www.hivglasgow.org/wp-content/uploads/2020/11/P053-van-Welzen.pdf>

Overton ET, Richmond G, Rizzardini G, et al. Long-acting cabotegravir + rilpivirine every 2 months: ATLAS-2M week 152 results. Poster H03. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); February 12-16 2022; Virtual. <https://www.croiconference.org/abstract/long-acting-cabotegravir-rilpivirine-every-2-months-atlas-2m-week-152-results/>

Segal-Maurer S, DeJesus E, Stellbrink H-J, et al. Capsid inhibition with lenacapavir in multidrug-resistant HIV-1 infection. *N Engl J Med.* 2022;386(19):1793-1803. doi:10.1056/NEJMoa2115542

Spinner C, Stoehr A, Wong A, et al. Starting or switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in clinical practice: Pooled 12-month results from the global BICSTaR study. Abstract P046. Presented at: HIV Glasgow; October 23-26 2020; Virtual. [https://www.hivglasgow.org/wp-content/uploads/2020/11/P046\\_Spinner.pdf](https://www.hivglasgow.org/wp-content/uploads/2020/11/P046_Spinner.pdf)

Woodcock A, Bradley C. Validation of the HIV Treatment Satisfaction Questionnaire (HIVTSQ). *Qual Life Res.* 2001;10(6):517-531. doi:10.1023/A:1013050904635

## **Glossary**

AE, adverse event  
ART, antiretroviral therapy  
ARV, antiretroviral  
BIC, bictegravir  
BICSTaR, bictegravir single tablet regimen  
CAB, cabotegravir  
CD, cluster of differentiation  
DDI, drug-drug interactions  
FTC, emtricitabine  
HIV, human immunodeficiency virus  
HIVTSQc, HIV Treatment Satisfaction Questionnaire-change  
HIVTSQs, HIV Treatment Satisfaction Questionnaire-status  
HRQOL, health-related quality of life  
IQR, interquartile range  
INSTI, integrase strand transfer inhibitor  
NNRTI, nonnucleoside reverse transcriptase inhibitor  
LEN, lenacapavir  
LS, least squares  
OBR, optimized background regimen  
PI, protease inhibitor  
PLWH, people living with HIV  
Q4W, once every four weeks  
Q8W, once every eight weeks  
QD, once per day  
QOL, quality of life  
RNA, ribonucleic acid  
RPV, rilpivirine  
SC, subcutaneous  
SF-36, 36-Item Short Form Survey  
T2DM, type 2 diabetes mellitus  
TAF, tenofovir alafenamide  
TE, treatment emergent  
w/, with